Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530026 | 0.81 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL23534412 | 0.78 | — | — | |
| SCHEMBL24737525 | 0.77 | DRD2 (0.40) | — | |
| SCHEMBL31658599 | 0.77 | DRD2 (0.40) | — | |
| SCHEMBL23454381 | 0.76 | KDM1A (0.40) | — | |
| SCHEMBL3464786 | 0.75 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL29180518 | 0.73 | SLC6A2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL30801024 | 0.73 | SLC6A2 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL27191319 | 0.72 | RECQL (0.36) | TDP1 | |
| SCHEMBL1481609 | 0.71 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA7CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | KHORA SPV 1, LLC | 2025-05-22 | — | — | US | disclosed |
| EP-4469062-A1 | INHIBITORS OF CDK4/6 KINASE | Kinnate Biopharma Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-119013030-A | Inhibitors of CDK4/6 kinase | 金耐特生物制药公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023147372-A1 | INHIBITORS OF CDK4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163063-A1 | INHIBITORS OF CDK4/6 KINASE | CDK4, CDK6, CDK2 | CHRNB2 4866/4885CHRNA3 4860/4885CHRNA7 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.